<html>
<head><title>
Prepared and filed by St Ives Financial
</title>
</head>
<body bgcolor="#FFFFFF">
<page>
 <p align="center"><font size="2" face="serif"><b>UNITED STATES<br>
  SECURITIES AND EXCHANGE COMMISSION<br>
 WASHINGTON, D.C. 20549</b></font></p>
 <p align="center"><b><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FORM
8-K</font></b></p>
<p align="center"><b><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CURRENT
      REPORT</font></b><font size="2" face="serif"><br>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</font></p>
<p align="center"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Date
    of Report (Date of earliest event reported): October 30, 2006</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="4" face="serif"><b>Savient Pharmaceuticals, Inc.</b></font></td>
</tr>
<tr valign="top">
  <td align="center"><hr noshade size="1">
    </td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(Exact Name of Registrant
    as Specified in Charter)</font></td>
</tr>
</table>

<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top">
  <td align="center">&nbsp;</td>
  <td align="center">&nbsp;</td>
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif"><b>Delaware</b></font></td>
<td width="34%" align="center"><font size="2" face="serif"><b>0-15313</b></font></td>
<td width="33%" align="center"><font size="2" face="serif"><b>13-3033811</b></font></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">(State or Other Juris-<br>diction of Incorporation</font></td>
<td align="center"><font size="2" face="serif">(Commission<br>File Number)</font></td>
<td align="center"><font size="2" face="serif">(IRS Employer<br>Identification No.)</font></td>
</tr>
</table>
<br><br>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top">
<td align="center"><font size="2" face="serif"><b>One Tower Center, 14th Floor</b></font><b><br>
    <font size="2" face="serif">East Brunswick, New Jersey 08816</font></b></td>
</tr>
<tr valign="top">
  <td align="center"><hr noshade size="1">
    </td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">(Address of Principal Executive Offices) (Zip Code)</font></td>
</tr>
<tr valign="top">
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">Registrant&#146;s telephone
    number, including area code: (732) 418-9300</font></td>
</tr>
<tr valign="top">
  <td align="center">&nbsp;</td>
</tr>
<tr valign="top">
  <td align="center"><hr noshade size="1">
    </td>
</tr>
<tr valign="top">
  <td align="center"><font size="2" face="serif">(Former Name or Former Address,
    if Changed Since Last Report)</font></td>
</tr>
</table>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i>see</i> General Instruction A.2. below):</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<img src="emptybox.gif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>

<p><a href="#contents"></a></p>
<p align="left"><font size="2" face="serif"><b>Item 2.02.&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition</b></font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October 30, 2006, Savient Pharmaceuticals, Inc. (the &#147;Registrant&#148;)
announced its financial results for the quarter and nine months ended September

30,
2006. The
full text of the press release issued in connection with the announcement is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
    addition, on October 31, 2006, the Registrant held a publicly available live
    webcast discussion of its financial results for the quarter ended September
     30, 2006. The transcript of the October 31, 2006 conference call is furnished
    as
    Exhibit
99.2 to this Current Report on Form 8-K.</font></p>
<p align="left"><font size="2" face="serif"><b>Item 9.01&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</b></font></p>
<p align="left"><font size="2" face="serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhibits</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Exhibit Index attached hereto.</font></p>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>

<p><a href="#contents"></a></p>
<p align="center"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNATURE</font></p>
<p align="left"><font size="2" face="serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.</font></p>
<table width="100%" cellspacing="0" cellpadding="0" border="0">
<tr valign="top"> <td align="left"><font size="1" face="serif">&nbsp;</font></td>
<td align="left"><font size="2" face="serif">SAVIENT PHARMACEUTICALS, INC.</font></td> </tr>
<tr valign="top">
  <td align="left">&nbsp;</td>
  <td align="left">&nbsp;</td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">Date:  November 2, 2006</font></td>
<td align="left"><font size="2" face="serif">By: <u>/s/ Philip K. Yachmetz&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></font></td>
</tr>
<tr valign="top">
<td align="left"><font size="2" face="serif">&nbsp;</font></td>
<td><font size="2" face="serif">Philip K. Yachmetz</font><br><font size="2" face="serif">Executive Vice President &amp; <br>Chief Business Officer</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
<div style="page-break-before:always"></div>
<page>

<p align="center"><font size="2" face="serif">EXHIBIT INDEX</font></p>
<table width="100%" cellspacing="0" cellpadding="0" align="center" border="0">
<tr valign="top" bgcolor="#FFFFFF">
<td align="left"><font size="2" face="serif"><u>Exhibit No.</u></font></td>
<td align="left" width="2%">&nbsp;</td>
<td width="89%" align="left"><font size="2" face="serif"><u>Description</u></font></td>
</tr>
<tr valign="top">
<td align="center"><font size="2" face="serif">99.1</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Press release dated October 30,
    2006</font></td>
</tr>
<tr valign="top">
<td align="center"></td>
<td align="left">&nbsp;</td>
<td align="left"></td>
</tr>
<tr valign="top" bgcolor="#FFFFFF">
<td align="center"><font size="2" face="serif">99.2</font></td>
<td align="left">&nbsp;</td>
<td align="left"><font size="2" face="serif">Transcript dated October 31, 2006</font></td>
</tr>
</table>
<p align="center">&nbsp;</p>
<hr noshade align="center" width="100%" size="2">
</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "b415439_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 8457}]
{"company-data": {"conformed-name": "SAVIENT PHARMACEUTICALS INC", "cik": "0000722104", "assigned-sic": "2833", "irs-number": "133033811", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-15313", "film-number": "061182816"}, "business-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816", "phone": "7324189300"}, "mail-address": {"street1": "ONE TOWER CENTER", "city": "EAST BRUNSWICK", "state": "NJ", "zip": "08816"}, "former-company": {"former-conformed-name": "BIO TECHNOLOGY GENERAL CORP", "date-changed": "19920703"}}
Prepared and filed by St Ives Financial
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
      REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
    of Report (Date of earliest event reported): October 30, 2006
Savient Pharmaceuticals, Inc.
(Exact Name of Registrant
    as Specified in Charter)
Delaware
0-15313
13-3033811
(State or Other Juris-
diction of Incorporation
(Commission
File Number)
(IRS Employer
Identification No.)
One Tower Center, 14th Floor
East Brunswick, New Jersey 08816
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone
    number, including area code: (732) 418-9300
(Former Name or Former Address,
    if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02.   Results of Operations and Financial Condition
On
October 30, 2006, Savient Pharmaceuticals, Inc. (the "Registrant")
announced its financial results for the quarter and nine months ended September

30,
2006. The
full text of the press release issued in connection with the announcement is
furnished as Exhibit 99.1 to this Current Report on Form 8-K.
In
    addition, on October 31, 2006, the Registrant held a publicly available live
    webcast discussion of its financial results for the quarter ended September
     30, 2006. The transcript of the October 31, 2006 conference call is furnished
    as
    Exhibit
99.2 to this Current Report on Form 8-K.
Item 9.01   Financial Statements and Exhibits
(d)      Exhibits
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
SAVIENT PHARMACEUTICALS, INC.
Date:  November 2, 2006
By:
/s/ Philip K. Yachmetz
Philip K. Yachmetz
Executive Vice President &
Chief Business Officer
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated October 30,
    2006
99.2
Transcript dated October 31, 2006